unknown
Stage
2020
Founded
1
Investors
About
Valitor develops biopharmaceuticals using a proprietary platform technology from UC Berkeley, focusing on long-acting anti-VEGF therapies for exudative retinal diseases as well as treatments in immuno-oncology and inflammatory joint diseases.
Explore Valitor's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.